Clinical Trial Update: The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression. [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating safety and efficacy of psilocybin for treatment-resistant depression in adults with bipolar II disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Ii Disorder
• Treatment-resistant Depression

Drugs mentioned

• Psilocybin (psilocybin)

Snippet

Sponsor: Sheppard Pratt Health System | Conditions: Treatment Resistant Depression | Phase 2 | Status: UNKNOWN